Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD5 | P21918 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303648 | 1.00 | MAOA (0.42) | MAOADRD2DRD1DRD4DRD5 | |
| SCHEMBL3314475 | 0.76 | DRD2 (0.47) | MAOADRD2DRD1DRD4DRD5 | |
| SCHEMBL28449155 | 0.75 | KMT2A (0.40) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL3311778 | 0.74 | KCNN2 (0.38) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL22044650 | 0.72 | KMT2A (0.51) | MAOADRD2DRD1DRD4DRD5 | |
| SCHEMBL8021988 | 0.72 | KMT2A (0.51) | MAOADRD2DRD1DRD4DRD5 | |
| SCHEMBL6643136 | 0.72 | DRD2 (0.37) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL13770917 | 0.68 | — | — | |
| SCHEMBL4752619 | 0.68 | DRD2 (0.43) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL3308280 | 0.68 | MAOA (0.44) | MAOADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309542-B2 | Substituted pyrrolidine amides, the production thereof, and the use thereof as medications | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| EP-2132193-B1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2008135526-A1 | CARBOXYLIC ACID AMIDES AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-13 | — | — | WO | disclosed |
| US-7235538-B2 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| US-7235538-B2 | Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV | NOVO NORDISK A/S (DK) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | DDC, GLS, UROD | MAOA 856/4885DRD2 60/4885DRD1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.